Kim, R. D., Poklepovic, A. S., Nixon, A. B., Kim, D. W., Soares, H. P., Kim, J., … Sanoff, H. K. (2018). Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers. In Journal of Clinical Oncology (Vol. 36, pp. 4082–4082). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.4082

Kim, Richard D., Andrew Stewart Poklepovic, Andrew B. Nixon, Dae Won Kim, Heloisa P. Soares, Jongphil Kim, Jun Min Zhou, Fatima Tariq, Natalie Burgess, and Hanna Kelly Sanoff. “Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.” In Journal of Clinical Oncology, 36:4082–4082. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.4082.

Kim RD, Poklepovic AS, Nixon AB, Kim DW, Soares HP, Kim J, et al. Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 4082–4082.

Kim, Richard D., et al. “Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 4082–4082. Crossref, doi:10.1200/jco.2018.36.15_suppl.4082.

Kim RD, Poklepovic AS, Nixon AB, Kim DW, Soares HP, Kim J, Zhou JM, Tariq F, Burgess N, Sanoff HK. Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 4082–4082.